HC Wainwright Reaffirms Buy Rating for Chimerix (NASDAQ:CMRX)

Chimerix (NASDAQ:CMRX - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $11.00 price target on the biopharmaceutical company's stock.

A number of other analysts also recently issued reports on the company. Wedbush restated an "outperform" rating and issued a $6.00 price target on shares of Chimerix in a research report on Thursday. StockNews.com upgraded Chimerix from a "sell" rating to a "hold" rating in a research report on Wednesday, August 21st.

Chimerix Price Performance

Shares of NASDAQ CMRX traded up $0.05 during midday trading on Monday, reaching $1.04. 341,524 shares of the stock traded hands, compared to its average volume of 354,807. The stock has a market capitalization of $93.23 million, a PE ratio of -1.11 and a beta of 1.13. Chimerix has a one year low of $0.75 and a one year high of $1.30. The company's 50 day moving average is $0.90 and its 200 day moving average is $0.91.

Chimerix (NASDAQ:CMRX - Get Free Report) last posted its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting analysts' consensus estimates of ($0.23). The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $1.26 million. During the same quarter in the prior year, the company posted ($0.21) earnings per share. As a group, equities analysts forecast that Chimerix will post -0.91 EPS for the current year.

Institutional Trading of Chimerix

Several institutional investors and hedge funds have recently made changes to their positions in the business. Acadian Asset Management LLC lifted its position in shares of Chimerix by 15.5% during the first quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock worth $2,304,000 after purchasing an additional 291,981 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its position in shares of Chimerix by 66.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Marshall Wace LLP bought a new stake in shares of Chimerix during the second quarter worth $137,000. Valeo Financial Advisors LLC increased its stake in shares of Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 69,505 shares during the period. Finally, Koshinski Asset Management Inc. purchased a new position in shares of Chimerix during the first quarter valued at $42,000. 45.42% of the stock is currently owned by institutional investors.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.